TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Life-threatening marrow failure of nonmalignant etiology meeting two of the three following criteria: granulocytes \< 500/mm\^3; a corrected reticulocyte count \< 1%; platelet count \< 20,000/mm\^3~* Failure to respond to the best available immunosuppressive treatment protocol by 75 days after initiation of therapy~* Lack of an HLA-identical family member or closely matched (9 or 10 of 10 HLA-locus match) unrelated marrow donor~* DONOR: Unrelated UCB unit matched for at least 4 of 6 loci~* DONOR: Related UCB unit matched for at least 3 of 6 lock~* Selection of the UCB unit(s) will be based upon matching or mismatching at HLA-A, B antigen level and DRB1 allele level typing; while HLA-C antigen/allele and HLA-DQB1 antigen/allele level typing are not considered in the matching criteria, if available each may be used to optimize unit selection~* Multiple UCB units are allowed to provide sufficient cell dose; when multiple units are selected, the following rules apply: a) the UCB unit with the least HLA disparity will be selected first (i.e., selection priority is 6/6 match \> 5/6 match \> 4/6 match), additional UCB units may be selected to increase cell dose; b) UCB units must be matched to each other for at least 4 of 6 loci; c) each unit must contain at least 1.5 x 10\^7 Total Nucleated Cells per kg recipient weight; d) the total cell dose of the combined units must be at least 3.0 x 10\^7 Total Nucleated Cells per kg recipient weight~Exclusion Criteria:~* Severe disease other than aplastic anemia that would severely limit the probability of survival during the graft procedure; patients who present with active fungal infections must be treated to resolve this problem before beginning the conditioning regimen~* HIV seropositive patients~* Patients who have developed clonal cytogenetic abnormalities or a myelodysplastic syndrome (these patients will be considered in separate protocols for myelodysplastic syndrome, etc.)~* Patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia~* Patients \> 40 years of age~* Related or unrelated cord blood units with \< 1.5 x 10\^7 Total Nucleated Cells per kg recipient weight~* Related or unrelated cord blood units without full testing and negative results for hepatitis A, B, C, HIV, HTLV-1, CMV viruses

- Gender: ALL
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): See Detailed Description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed AL amyloidosis~  * Persistent or recurrent disease after 1 course of prior high-dose chemotherapy~* Previously treated with autologous stem cell transplantation~* Significant initial improvement in organ function after prior high-dose melphalan, defined by at least 1 of the following:~  * Complete hematologic remission (e.g., absence of monoclonal spike by immunofixation in serum and urine AND less then 5% plasma cells in bone marrow with no clonal predominance) OR partial hematologic response (e.g., any decrease in serum or urine monoclonal protein OR decrease in bone marrow plasmacytosis)~ * Greater than 50% reduction in proteinuria with preservation of creatinine clearance~ * Greater than 50% reduction in alkaline phosphatase OR at least 2 cm decrease in liver size by physical exam~ * Subjective neurologic improvement, as confirmed by neurologist~ * Cardiac stabilization of disease confirmed by echocardiography defined as less than 2 mm increase in mean wall thickness and/or less than 20 g increase in left ventricular mass~ * Improvement in performance status\* NOTE: \*This criteria alone does not constitute significant improvement in organ function~* Prior stem cell yield must have been ≥ 2 x 10\^6 CD34+ cells/kg~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~* No chemotherapy after first transplantation~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* Southwest Oncology Group- 0-2~Life expectancy~* More than 6 months~Hematopoietic~* See Disease Characteristics~Hepatic~* See Disease Characteristics~Renal~* See Disease Characteristics~Cardiovascular~* See Disease Characteristics~* Left ventricular ejection fraction ≥ 45% by multiple gated acquisition scan or echocardiogram~Pulmonary~* diffusing capacity of lung for carbon monoxide ≥ 50%~Exclusion Criteria:~* No myelodysplastic syndromes~* No abnormal bone marrow cytogenetics~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Acceptable toxicity from first transplantation, confirmed by the transplant team~* HIV negative~* No other concurrent malignancy except treated skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 2nd Stem Cell Transplant (Type: EXPERIMENTAL): Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High risk survivors of cardiac arrest~* Decision by potential subject's clinical team to use our institutional standard invasive, multimodal neurologic monitoring for post-arrest care~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiac arrest (Type: EXPERIMENTAL): Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Turkish Adaptation, Validity and Reliability of Exercise Sensitivity Questionnaire

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Being older than 35 years,~* Having a self-reported heart disease (heart failure, acute myocardial infarction, coronary artery disease, coronary by-pass surgery, heart valve surgery, history of stable angina, cardiac have battery)~* To have agreed to participate in the study,~* have internet access,~* Being a mother tongue Turkish.~* Carrying at least two of the cardiac risk factors (hypertension, Type 2 diabetes, hyperlipidemia/dyslipidemia, overweight or obesity (BMI\>25), physical inactivity (less than 150 minutes of moderate-intensity exercise per week, smoking)~Exclusion Criteria:~* Not answering all questions~* Cognitive defect or cooperation disorder

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients, aged 2 to 6 years presenting tympanic temperature ≥ 38.5 ° C and no greater than 39.5° C, associated with acute upper respiratory tract infections~* Parents or legal representatives who have provided written informed consent and provided a phone number for the call at end of study~Exclusion Criteria:~* History of hypersensitivity to any drugs or excipients of the study~* Any medication, surgical, or medical condition, which might significantly alter the absorption, distribution, metabolism, or excretion of medications~* Background or suspected hematological disorders, febrile seizures, asthma, peptic ulcer or gastrointestinal bleeding~* Neurological and hemodynamics disorders~* Evidence of liver or kidney impairment or heart failure~* Patients who have received previous treatment with antipyretics; acetaminophen (up to 4 hrs), NSAIDs (up to 6 hrs) or antibiotic therapy (at least 12 hours)~* Any surgical or medical condition, which in the opinion of the investigator, may place the patient at risk~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac potassium (Type: EXPERIMENTAL): None
- Acetaminophen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
1. Documentation of Disease:~   1.1 Diagnosis of Chronic Myelogenous Leukemia (CML) in chronic phase. Patients in either accelerated or blastic phases are not eligible. Clonal cytogenetic evolution alone does not exclude patients. See Appendix I for definitions of accelerated and blastic phases of CML.~   1.2 Patients in whom a Philadelphia chromosome \[t(9;22)\] is not detectable by cytogenetic studies are eligible if they meet one of the following criteria:~  * BCR/ABL protein detectable by immunoblotting~  * BCR/ABL rearrangement detectable by Southern blot analysis~  * Polymerase chain reaction (PCR) positive fusion transcripts for BCR/ABL~  * BCR/ABL translocation present by fluorescence in situ hybridization (FISH).~2. Prior Treatment:~   2.1 No previous therapy with homoharringtonine (HHT)~   2.2 No more than six months cumulative (\<180 days) of prior hydroxyurea (HU) therapy. However, patients may not have received more than 60 days of HU treatment after failing interferon. Patients with previous intolerance or failure to respond to HU are not eligible.~   2.3 Patients must have failed an adequate trial (5M units/m2/day) of alpha-Interferon (IFN) or IFN/ara-C to be eligible, as defined below (any ONE of the following):~  * Failure to achieve a complete hematologic response after 6 months of IFN therapy.~  * Failure to achieve any cytogenetic response (i.e., still 100% Ph+) after 12 months of IFN therapy.~  * Intolerable adverse effects of IFN therapy after at least one month of IFN treatment. Significant documented toxicity of ≥ grade 3 (using NCI Common Toxicity Criteria guidelines) due to IFN is required.~  * Loss of a prior hematologic remission or cytogenetic response to IFN.~  * A two-fold increase in WBC count when compared to WBC count when IFN therapy was initiated.~3. Age ≥ 16 years~4. Patients with uncontrolled tachyarrhythmias (such as, atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular tachycardias not adequately controlled) are not eligible.~5. Non-pregnant and non-nursing. Treatment under this protocol would expose an unborn child to significant risks. Women and men of reproductive potential should agree to use an effective means of birth control.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Homoharringtonine (Type: EXPERIMENTAL): None
- Hydroxyurea (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Periodontal Diseases on Vascular Parameters in Patients Suffering of Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* -Men- \>40 years~* moderate and severe generalized chronic periodontitis~* Former diagnosis of hypertension~* \>12 teeth~Exclusion Criteria:~* \>70 years~* smokers (\>10 cig/day)~* body mass index\>30~* Need of antibioprophylaxis~* Medical treatment including anti-inflammatory drugs and/or antibiotics~* Refractory form of hypertension- aggressive periodontitis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- blood and cardiological examination (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart decompensation requiring hospitalization and the use of intravenous diuretic therapy~* Left Ventricular Ejection Fraction ≤ 40%.~Exclusion Criteria:~* Hospitalization for cardiac decompensation leading to an invasive procedure (valve, coronary, etc.).~* Acute reversible cause of heart failure.~* Incurable disease (other than heart failure) or estimated life expectancy of less than one year.~* Patient transferred directly to another department or cardiac rehabilitation center.~* Significant cognitive impairment.~* Patient without cell phone or email.~* Linguistic or psychic refusal or inability to sign the informed consent.~* Current participation in a clinical tria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- multi-intervention (Type: EXPERIMENTAL): * Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.~* Automatic creation of documents for patient:~  * Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.~ * Drug prescription.~ * Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).~ * Therapeutic education documents~* Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously
- Control (Type: NO_INTERVENTION): Discharge prescription according to the investigator's habits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Capsular Tension Rings in Intraocular Lens Rotation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
\*\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\*\*~Inclusion Criteria:~* Active duty and DoD beneficiaries aged 30 years or older undergoing cataract surgery~* Corneal astigmatism ≥ 1.0 D and a surgical plan that includes a toric intraocular lens for astigmatism correction. (The lens used will be the TECNIS IOL. It will be used on label)~* No observed zonular or capsular problems prior to, or at the time of, capsular tension ring insertion~Exclusion Criteria:~* Patients undergoing cataract surgery who do not have corneal astigmatism ≥1.0 D.~* Any observed zonular or capsular problems prior to, or at the time of, capsular tension ring insertion.~* Pre-existing ocular conditions, including:Pre-existing ocular conditions, including:~  * Pseudoexfoliation syndrome in one or both eyes~ * Prior incisional ocular surgery~ * Lens subluxation~ * Poor dilation or inability to position at the slit lamp (making postoperative outcome measurements difficult or impossible)~ * Plans for extensive travel or to move away during the postoperative evaluation period~ * Other conditions that would influence the capsule or lens positioning~* Surgical plan to include other procedures at the time of initial cataract surgery, such as Limbal Relaxing Incisions (LRIs), Micro-Incisional Glaucoma Surgery (MIGS), etc.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group: toric IOL plus capsular tension ring (Type: EXPERIMENTAL): None
- Control group: toric IOL only (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age from 18 to 64 years at entry~2. Patients with mitral and/or aorthic valve bioprosthesis for at least 3 months postoperatively~3. There is 12-lead electrocardiogram documented AF on the day of screening or randomization; or a 24-hour Holter electrocardiogram recording showing AF episodes postoperatively~4. Brain computed tomography scan without hemorrhage or findings of acute cerebral infarction on the last 2 days of screening~5. Exclusion of atrial thrombus or valve prosthesis thrombosis by transesophageal echocardiograph on the last 2 days of screening~6. Written, informed consent~Exclusion Criteria:~1. Previous hemorrhagic stroke~2. Ischemic stroke in the last 6 months~3. Severe renal impairment (creatinine clearance rates \< 30 ml/min)~4. Active liver disease (any etiology)~5. Concomitant use of any antiplatelet (aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine, etc)~6. Increased risk of bleeding (congenital or acquired)~7. Uncontrolled hypertension~8. Gastrointestinal hemorrhage within the past year~9. Anemia (hemoglobin level \<10 g/dL) or thrombocytopenia (platelet count \< 100 × 109/L)~10. Active infective endocarditis~11. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Dabigatran 110 mg BID
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin adjusted-dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility